JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY) ›› 2016, Vol. 30 ›› Issue (3): 24-28.doi: 10.6040/j.issn.1673-3770.0.2015.340

Previous Articles     Next Articles

Bioinformatic screening of differentially expressed protein kinases and their inhibitors in hypopharyngeal cancer.

HU Wenliang, ZHENG Yanqiu, CUI Xiaobo, CUI Yanru, SUN Yuanhao   

  1. Department of Otolaryngology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, Inner Mongolia, China
  • Received:2015-08-15 Online:2016-06-16 Published:2016-06-16

Abstract: Objective To screen differentially expressed protein kinases and their inhibitors, in order to provide new targets for molecular therapy of hypopharyngeal cancer. Methods GEO database and SAM software were employed to screen the differentially expressed protein kinase genes in hypopharyngeal cancer. Human hypopharyngeal cancer FaDu cell line was cultured in vitro. Real-time PCR was used to prove the accuracy of microarray results. Based on KEGG database, the kinase-regulated pathways were identified. The inhibitors of such kinases were identified by using kinase-inhibitor database. Results A total of 3 protein kinase genes(PKC-β, CDK6 and CDC42)were identified(fold change≥2.0, P<0.05). Real-time PCR showed that the 3 kinase genes were differentially expressed in FaDu cells, which was consistent with the microarray results(P<0.05)Pathway analysis indicated that a complex pathway network was regulated by the 3 kinases. The results of inhibitor screening showed that 5 inhibitors regulated PKC-β, 4 inhibitors regulated CDK6 and 3 inhibitors regulated CDC42. There were less than 10 studies about the 4 inhibitors in cancer. Conclusion Three differentially expressed protein kinases(PKC-β, CDK6 and CDC42)are identified and they are able to promote the development of tumor. Their kinase inhibitors may play a potential anti-cancer role, which may provide a new target for molecular therapy of hypopharyngeal cancer.

Key words: Bioinformatics, Protein kinase, Kinase inhibitor, Hypopharyngeal cancer

CLC Number: 

  • R739.65
[1] Gourin C G, Terris D J. Carcinoma of the hypopharynx[J]. Surg Oncol Clin N Am, 2004, 13(1):81-98.
[2] Buckley J G, MacLennan K. Cervical node metastases in laryngeal and hypopharyngeal cancer: a prospective analysis of prevalence and distribution[J]. Head Neck, 2000, 22(4):380-385.
[3] American Society of Clinical Oncology, Pfister D G, Laurie S A, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer[J]. J Clin Oncol, 2006, 24(22):3693-3704.
[4] Piirsoo A, Kasak L, Kauts M L, et al. Protein kinase inhibitorSU6668 attenuates positive regulation of Gli proteins in cancer[J]. Biochim Biophys Acta, 2014, 1843(4):703-714.
[5] Manning G, Whyte D B, Martine R, et al. The protein kinase complement of the human genome[J]. Science, 2002, 298(5600):1912-1934.
[6] Okkenhaug K. Signaling by the phosphoinositide 3-kinase family inimmune[J]. Annu Rev Immunol, 2013, 31:675-704.
[7] Kizub I V, Klymenko K I, Soloviev A I. Protein kinase C in enhanced vascular tone in diabetes mellitus[J]. Int J Cardiol, 2014, 174(2):230-242.
[8] Barrett T, Suzek T O, Troup D B, et al. NCBI GEO: mining millions of expression profiles-database and tools[J]. Nucleic Acids Res, 2005, 33(Database issue):D562-566.
[9] Joost S, Kalbermatten M, Bonin A. Spatial analysis method(sam): a software tool combining molecular and environmental data to identify candidate loci for selection[J]. Mol Ecol Resour, 2008, 8(5):957-960.
[10] Basson M D, Zeng B, Downey C, et al. Increased extracellular pressure stimulates tumor proliferation by a mechanosensitive calcium channel and PKC-β[J]. MolOncol, 2015, 9(2):513-526.
[11] He L F, Wang T T, Gao Q Y, et al. Stanniocalcin-1 promotes tumor angiogenesis through up-regulation of VEGF in gastric cancer cells[J]. J Biomed Sci, 2011, 18(1):39-48.
[12] Fridberg M, Kjellström S, Anagnostaki L, et al. Immunohistochemical analyses of phosphatases in childhood B-cell lymphoma: lower expression of PTEN and HePTP and higher number of positive cells for nuclear SHP2 in B-cell lymphoma cases compared to controls[J]. Pediatr Hematol Oncol, 2008, 25(6):528-540.
[13] Xiao F, Zhang W, Zhou L, et al. microRNA-200a is an independent prognostic factor of hepatocellular carcinoma and induces cell cycle arrest by targeting CDK6[J]. Oncol Rep, 2013, 30(5):2203-2210.
[14] Xia B, Yang S, Liu T, et al. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6[J]. Mol Cancer, 2015, 14(1):57-70.
[15] Comstock C E, Augello M A, Goodwin J F, et al. Targeting cell cycle and hormone receptor pathways in cancer[J]. Oncogene, 2013, 32(48):5481-5491.
[16] Zen Y, Harada K, Sasaki M, et al. Intrahepatic cholangio carcinoma escapes from growth inhibitory effect of transforming growth factor-beta1 by overexpression of cyclin D1[J]. Lab Invest, 2005, 85(4):572-581.
[17] Wang J, Li X, Lu X, et al. The regulation of stat3 signal transduction pathway to G1 to S phase of laryngo carcinoma cell[J]. Clin J Otorhinolarynol Head Neck Surg, 2008, 22(15):699-703.
[18] Kwon D Y, Lee H E, Weitzel D H, et al. Synthesis and Biological Evaluation of Manassantin Analogues for Hypoxia-Inducible Factor 1α Inhibition[J]. J Med Chem, 2015, 58(19):7659-7671.
[19] Zupa A, Improta G, Silvestri A, et al. A pilot characterization of human lung NSCLC by protein pathway activation mapping[J]. J Thorac Oncol, 2012, 7(12):1755-1766.
[20] Razidlo G L, Magnine C, Sletten A C, et al. Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion[J]. Cancer Res, 2015, 75(14):2907-2915.
[21] Cheung C H, Coumar M S, Chang J Y, et al. Aurora kinase inhibitor patents and agents in clinical testing: an update(2011-13)[J]. Expert Opin Ther Pat, 2014, 24(9):1021-1038.
[22] Murphy C G, Dickler M N. The Role of CDK4/6 Inhibition in Breast Cancer[J]. Oncologist, 2015, 20(5):483-490.
[23] Chen C, Song X, Ma S, et al. Cdc42 inhibitor ML141 enhances G-CSF-induced hematopoietic stem and progenitor cell mobilization[J]. Int J Hematol, 2015, 101(1):5-12.
[24] Gray J E, Altiok S, Alexandrow M G, et al. Phase 2 randomized study of enzastaurin(LY317615)for lung cancer prevention in former smokers[J]. Cancer, 2013, 119(5):1023-1032.
[25] Rampling R, Sanson M, Gorlia T, et al. A phase I study of LY317615(enzastaurin)and temozolomide in patients with gliomas(EORTC trial 26054)[J]. Neuro Oncol, 2012, 14(3):344-350.
[26] Blevins D P, Dadu R, Hu M, et al. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitortherapy for thyroid cancer[J]. Thyroid, 2014, 24(5):918-922.
[27] 潘新良, 雷大鹏, 许风雷, 等. 下咽癌的外科治疗[J]. 山东大学耳鼻喉眼学报, 2007, 21(1):1-6. PAN Xinliang, LEI Dapeng, XU Fenglei, et al. Surgical treatment of lower pharyngeal carcinoma[J]. J Otolaryngol Ophthalmol Shandong Univ, 2007, 21(1):1-6.
[1] DONG Pin, YING Xinjiang, CHEN Xinwei, DENG Zhihong, ZHANG Shaoqiang, YU Ziwei, JIN Bin, SUN Zhenfeng, XIE Jin, ZHU Jiangcai. Preliminary clinical analysis of neo-adjuvant chemotherapy with nimotuzumab plus nedaplatin and fluorouracil in hypopharyngeal squamous cell carcinoma. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(3): 10-14.
[2] LI Xiaoming, SONG Qi, LI Hongxia, TAO Zhenfeng, SHEN Yupeng, XIAO Shufen. Reconstruction of hypopharyngeal defects after ablation of advanced head and neck squamous carcinoma involving hypophaynx with pectoralis major myocutaneous flap. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(3): 4-9.
[3] LI Wenming, WEI Dongmin, SUN Ruijie, QIAN Ye, LIU Dayu, XIE Guang, LEI Dapeng, PAN Xinliang. Surgical treatment of hypopharyngeal cancer with cervical esophageal invasion. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(3): 15-19.
[4] GAO Zhenfeng, TAO Qian, CAI Xiaolan. Expression and significance of ERK5 protein in nasal polyps cells. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(1): 40-42.
[5] ZHENG Li-you. null [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2012, 26(6): 31-33.
[6] LIANG Hui1,2, PAN Xinliang1, MA Chao3, WANG Qirong2, HAN Fei2, CUI Zhaoyang2. Invasion of the CD133-positive cells in FADU cell line [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2010, 24(2): 5-7.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!